Management of adverse effects in CAR T-cell therapy
Immunotherapies such as immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapy are emerging as new treatments for relapsed and/or refractory hematological malignancies. CAR T-cell therapy has attracted attention as a potentially curative treatment for patients incurable by chemotherapy. However, appropriate management is required to avoid serious complications specific to CAR T-cell therapy, such as cytokine release syndrome (CRS), neurotoxicity (ICANS), hypogammaglobulinemia and prolonged cytopenia, as well as post-treatment infections caused by suppressed immune function.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Rinsho ketsueki] The Japanese journal of clinical hematology - 64(2023), 9 vom: 27., Seite 1203-1212 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Goto, Hideki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Bispecific |
|---|
| Anmerkungen: |
Date Completed 31.10.2023 Date Revised 31.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11406/rinketsu.64.1203 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363912126 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363912126 | ||
| 003 | DE-627 | ||
| 005 | 20231226094338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.11406/rinketsu.64.1203 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1212.xml |
| 035 | |a (DE-627)NLM363912126 | ||
| 035 | |a (NLM)37899201 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Goto, Hideki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of adverse effects in CAR T-cell therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.10.2023 | ||
| 500 | |a Date Revised 31.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Immunotherapies such as immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapy are emerging as new treatments for relapsed and/or refractory hematological malignancies. CAR T-cell therapy has attracted attention as a potentially curative treatment for patients incurable by chemotherapy. However, appropriate management is required to avoid serious complications specific to CAR T-cell therapy, such as cytokine release syndrome (CRS), neurotoxicity (ICANS), hypogammaglobulinemia and prolonged cytopenia, as well as post-treatment infections caused by suppressed immune function | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CAR-T | |
| 650 | 4 | |a CRS | |
| 650 | 4 | |a Chimeric antigen receptor | |
| 650 | 4 | |a ICANS | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho ketsueki] The Japanese journal of clinical hematology |d 1972 |g 64(2023), 9 vom: 27., Seite 1203-1212 |w (DE-627)NLM000222178 |x 0485-1439 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2023 |g number:9 |g day:27 |g pages:1203-1212 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11406/rinketsu.64.1203 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2023 |e 9 |b 27 |h 1203-1212 | ||